Clinical Trial Update: Senolytic Therapy to Modulate Progression of Alzheimer's Disease [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial investigating senolytic therapy to modulate progression of Alzheimer’s disease has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Snippet

Sponsor: The University of Texas Health Science Center at San Antonio | Conditions: Alzheimer Disease | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-03-06